scholarly journals Vacuum extractor AVE-1 in obstetric practice

2021 ◽  
Vol 43 (3) ◽  
pp. 87-88
Author(s):  
V. N. Mistrova ◽  
I. X. Khairullina

Recently, a vacuum extractor has become more widely used in obstetric practice. However, the assessment of its application has not yet been given to the proper extent, which prompted us to share our experience.

Anaesthesia ◽  
2001 ◽  
Vol 56 (10) ◽  
pp. 1023-1024 ◽  
Author(s):  
F. Plaat ◽  
L. McCready-Hall

2016 ◽  
pp. 11-18
Author(s):  
L. Nazarenko ◽  
◽  
L. Dubrova ◽  
O. Tarusмna ◽  
◽  
...  

The question of the prevention of pathologies of the labor is currently very important, the answer to them has become the favored formation of «dominants of delivery», choice of the optimal time to delivery, effective and safe method of induction, that promotes the promptness of the female organism and ripening of the cervix, as well as the timely identification and correction of pathological prelмmмnary period. In a review article describes the modern approaches and methods of preventing the pathology of labor activity, presented by the authors ‘ own experience regarding the use of prostaglandins, non-steroidal anti-inflammatory drugs, individual approach to the management of perinatal risk. Key words: childbirth, prevention, induction, prostaglandin, non-steroidal anti-inflammatory drugs.


2017 ◽  
pp. 19-24
Author(s):  
O.V. Grishchenko ◽  
◽  
V.V. Bobrytska ◽  

The objective: To evaluate the clinical efficacy and safety of Enoxaparin-Pharmex for the prevention of thrombotic complications (pulmonary embolism) in the postoperative period in patients with moderate risk of these complications. Patients and methods. The study included 50 women after a caesarean section had an average degree of risk of pulmonary embolism. Patients were divided into the main group (n=25) and control group (n=25) in accordance with the treatment: patients of the main group received postoperative Еnoxaparin- Pharmex, group comparisons enoxaparin sodium (brand foreign manufacturer’s). Patients in both groups received the drug at a dose of 20 mg for 5 days, 1 time per day subcutaneously. Results. The research data analysis showed identity results of hemostasiogram of patients in the main group and the comparison group, no side effects after treatment in both groups. Conclusion. The clinical studies suggest the drug Enoxaparin-Pharmex is effective, safe LMWH, which can be used to prevent troboembolic complications, including post-operative treatment in obstetric practice. Spectrum of Enoxaparin-Pharmex can be extended to the prevention and treatment of thromboembolic conditions of varying severity with appropriate doses of the drug. Key words: Enoxaparin-Pharmex, prevention of pulmonary embolism.


GYNECOLOGY ◽  
2014 ◽  
Vol 16 (2) ◽  
pp. 82-84
Author(s):  
Yu.B. Uspenskaya ◽  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document